Panel firm offers speedy trend analysis

Share this article:
All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
The service, Snapshot, can generate sample sizes in the hundreds across six countries, according to a release. For example, within hours of the FDA's decision to severely restrict use of GlaxoSmithKline diabetes pill Avandia, Snapshot closed a survey of 100 UK diabetes specialists and endocrinologists, with 63% saying the news would encourage their use of a DPP 4 inhibitor/GLP 1 mimetic, 12% saying they would initiate insulin earlier, and 13% saying they would not change Rx habits.
Release of FDA ad-com briefing documents for weight-loss candidate Qnexa prompted a Snapshot survey of 730 US PCPs, with 82% saying they would recommend approval. In a follow-up survey of 398 PCPs after the ad-com voted 10-6 against approval, 68% said they would have recommended approval.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.